Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.31 |
| ▸ | ATR | Q13535 | 2/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | F10 | P00742 | 4/20 | 0.30 |
| ▸ | PLG | P00747 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23762144 | 0.92 | NR1H2 (0.40) | NR1H2ACACBESR2JAK2JAK3 | |
| SCHEMBL23751200 | 0.91 | F10 (0.33) | ABCB1MAPTF10PLGHRH3 | |
| SCHEMBL23762199 | 0.89 | NR1H2 (0.40) | NR1H2ACACBESR2JAK2JAK3 | |
| SCHEMBL29836532 | 0.89 | NR1H2 (0.40) | NR1H2ACACBESR2JAK2JAK3 | |
| SCHEMBL23751283 | 0.87 | NR1H2 (0.41) | NR1H2ACACBESR2JAK2JAK3 | |
| SCHEMBL29371186 | 0.87 | NR1H2 (0.42) | NR1H2ACACBESR2JAK2JAK3 | |
| SCHEMBL22802664 | 0.87 | NR1H2 (0.42) | NR1H2ACACBESR2JAK2JAK3 | |
| SCHEMBL29836527 | 0.87 | NR1H2 (0.41) | NR1H2ACACBESR2NAMPTJAK2 | |
| SCHEMBL23762208 | 0.87 | NR1H2 (0.41) | NR1H2ACACBESR2NAMPTJAK2 | |
| SCHEMBL23762087 | 0.86 | NR1H2 (0.41) | NR1H2ACACBESR2JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3807273-B1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2022-08-03 | — | — | EP | disclosed |
| US-20210253568-A1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253568-A1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | ROCK1, ROCK2, RHOA | NR1H2 1422/4885ACACB 2494/4885ESR2 3940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.